InsiderTrades.com logo
The secret supplier behind NVIDIA, Tesla and Microsoft
From Behind the Markets   |   Ad
The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.
Click here for the ticker >>>

SYRE Insider Trading

Insider Ownership Percentage: 6.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $10,929.00

Spyre Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Spyre Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Spyre Therapeutics Share Price & Price History

Current Price: $34.40
Price Change: ▼ Price Decrease of -0.41 (-1.18%)
As of 10/28/2024 01:00 AM ET

This chart shows the closing price history over time for SYRE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Urgent: This election is rigged
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

Spyre Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/25/2024Jeffrey W AlbersDirectorSell300$36.43$10,929.0034,060View SEC Filing Icon  
See Full Table
Protect Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings   |   Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.

SEC Filings (Institutional Ownership Changes) for Spyre Therapeutics (NASDAQ:SYRE)

80.39% of Spyre Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SYRE by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Spyre Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
10/23/2024Assenagon Asset Management S.A.1,142,768$33.61M0.1%N/A2.837%Search for SEC Filing on Google Icon
10/3/2024SG Americas Securities LLC12,589$0.37M0.0%+127.0%0.031%Search for SEC Filing on Google Icon
8/16/2024Perceptive Advisors LLC3,031,018$71.26M1.7%+18.6%7.524%Search for SEC Filing on Google Icon
8/16/2024Driehaus Capital Management LLC687,080$16.15M0.2%N/A1.706%Search for SEC Filing on Google Icon
8/15/2024The Manufacturers Life Insurance Company37,782$0.89M0.0%N/A0.094%Search for SEC Filing on Google Icon
8/15/2024Darwin Global Management Ltd.452,040$10.27M1.2%N/A1.122%Search for SEC Filing on Google Icon
8/15/2024Armistice Capital LLC136,000$3.20M0.0%N/A0.338%Search for SEC Filing on Google Icon
8/15/2024Affinity Asset Advisors LLC513,420$12.07M1.4%N/A1.275%Search for SEC Filing on Google Icon
8/14/2024Great Point Partners LLC134,612$3.17M0.6%N/A0.334%Search for SEC Filing on Google Icon
8/14/2024Logos Global Management LP575,000$13.52M1.1%N/A1.427%Search for SEC Filing on Google Icon
8/14/2024Farallon Capital Management LLC666,000$15.66M0.1%N/A1.653%Search for SEC Filing on Google Icon
8/14/2024Integral Health Asset Management LLC100,000$2.35M0.2%N/A0.248%Search for SEC Filing on Google Icon
8/14/2024Avoro Capital Advisors LLC1,839,138$43.24M0.6%N/A4.566%Search for SEC Filing on Google Icon
8/14/2024HighVista Strategies LLC113,550$2.67M1.0%N/A0.282%Search for SEC Filing on Google Icon
8/14/2024Profund Advisors LLC12,606$0.30M0.0%N/A0.031%Search for SEC Filing on Google Icon
8/13/2024Ensign Peak Advisors Inc82,475$1.94M0.0%N/A0.205%Search for SEC Filing on Google Icon
8/12/2024Amalgamated Bank1,198$28K0.0%N/A0.003%Search for SEC Filing on Google Icon
8/9/2024Carlyle Group Inc.9,620$0.23M0.0%N/A0.024%Search for SEC Filing on Google Icon
8/8/2024First Turn Management LLC464,435$10.92M1.8%N/A1.153%Search for SEC Filing on Google Icon
8/6/2024Quest Partners LLC1,523$36K0.0%N/A0.004%Search for SEC Filing on Google Icon
8/6/2024Candriam S.C.A.105,000$2.47M0.0%N/A0.261%Search for SEC Filing on Google Icon
8/3/2024TD Asset Management Inc35,168$0.83M0.0%N/A0.087%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers51,896$1.22M0.0%N/A0.129%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp117,686$2.77M0.0%N/A0.292%Search for SEC Filing on Google Icon
7/26/2024EFG Asset Management North America Corp.36,781$0.87M0.2%N/A0.091%Search for SEC Filing on Google Icon
7/12/2024SG Americas Securities LLC5,545$0.13M0.0%N/A0.014%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Spyre Therapeutics logo
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Read More on Spyre Therapeutics

Today's Range

Now: $34.40
Low: $34.29
High: $36.09

50 Day Range

MA: $29.22
Low: $24.76
High: $34.81

52 Week Range

Now: $34.40
Low: $8.43
High: $47.97

Volume

230,308 shs

Average Volume

511,872 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.92

Who are the company insiders with the largest holdings of Spyre Therapeutics?

Spyre Therapeutics' top insider shareholders include:
  1. Jeffrey W Albers (Director)
Learn More about top insider investors at Spyre Therapeutics.

Who are the major institutional investors of Spyre Therapeutics?

Spyre Therapeutics' top institutional shareholders include:
  1. Assenagon Asset Management S.A. — 2.84%
  2. SG Americas Securities LLC — 0.03%
Learn More about top institutional investors of Spyre Therapeutics stock.

Which institutional investors are buying Spyre Therapeutics stock?

In the previous quarter, SYRE stock was acquired by institutional investors including:
  1. Assenagon Asset Management S.A.
  2. SG Americas Securities LLC
The most serious warning of my career
From Porter & Company   |   Ad
With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election.
Click here now to grab your seat now.